The Sixth People's Hospital of Shenyang
12
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
33%
4 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)
Role: collaborator
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy
Role: collaborator
Timing of Endoscopy for Acute Variceal Bleeding in Patients With Cirrhosis
Role: collaborator
CHESS Criteria for Varices Screening in Compensated Advanced Chronic Liver Disease (CHESS2001/APPHA2001)
Role: collaborator
Simplified Treatment of Anti-retrovirus in China (C-STAR)
Role: collaborator
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
Role: collaborator
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Role: collaborator
Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
Role: collaborator
Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)
Role: collaborator
COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
Role: collaborator
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
Role: collaborator
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Role: collaborator
All 12 trials loaded